Drug intelligence / Profile preview

VV-Onco

Development stage: Preclinical
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies

Overview

VV-Onco is a specific oncolytic vaccinia virus strain that has been investigated for its ability to inhibit the proliferation of human hepatocellular carcinoma (HCC) cells. Its therapeutic action is mediated through multiple cellular pathways, including the induction of endoplasmic reticulum stress and autophagy, and the modulation of Wnt signaling pathways within the cancer cells. As an oncolytic virus, VV-Onco is designed to selectively infect and replicate within tumor cells, leading to their direct lysis and subsequently stimulating an anti-tumor immune response.

Other names: VV-Onco oncolytic strainoncolytic vaccinia virus

Beyond the preview

Go deeper on VV-Onco.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VV-Onco.

Explore the full profile